Wolfe v. Merrill National Laboratories, Inc.

433 F. Supp. 231
CourtDistrict Court, M.D. Tennessee
DecidedJune 13, 1977
Docket77-2005-NE-CV
StatusPublished
Cited by8 cases

This text of 433 F. Supp. 231 (Wolfe v. Merrill National Laboratories, Inc.) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wolfe v. Merrill National Laboratories, Inc., 433 F. Supp. 231 (M.D. Tenn. 1977).

Opinion

MEMORANDUM

MORTON, District Judge.

*233 This action is presently before the court on the motion of the United States of America (“the Government”) to have the court substitute it as the sole defendant and to dismiss the action for failure on plaintiff’s part to exhaust her administrative remedies. Both motions are predicated on the express provisions of the National Swine Flu Immunization Program, P.L. 94-380, 94th Cong., August 12, 1976 (“the Act”), amending Section 317 of the Public Health Service Act (42 U.S.C., § 247b).

The plaintiff resists both motions, alleging alternatively that the Act permits a suit such as this directly against a drug manufacturer, that the Act is not applicable to the facts of this case, and that even if it were, the portion of it which' limits her legal remedies to recovery under the provisions of the Federal Tort Claims Act (“the Tort Act”) is unconstitutional.

In accordance with plaintiff’s latter contention, she also seeks an injunction against further implementation of the Act.

. Plaintiff, 1 a licensed physician in the state of Tennessee, allegedly contracted a disease known as Gillane-Barre paralysis subsequent to her alleged self-administration of swine flu vaccine manufactured by one of the drug companies named as defendants in her complaint. The vaccine had been prepared and distributed under the auspices of the National Swine Flu Immunization Program (“the Act”). The Act provides for written consent forms and procedures to assure that the risks of inoculation with the vaccine are fully explained to a prospective inoculee and that information respecting the inoculee’s rights and remedies arising out of the administration of the vaccine is provided to him. Plaintiff alleges that she never signed any such forms (though she does not allege that she never saw or was unaware of such forms).

Plaintiff contends that her paralysis was a proximate result of her inoculation with swine flu vaccine, and that the defendant drug companies were negligent in testing the drug prior to its distribution and in failing to convey adequate warnings to the public as to the possibility of adverse reactions to the drug. Jurisdiction is alleged on the basis of diversity of citizenship.

Although the merits of this case are not presently before this court, certain facts are pertinent to the disposition of the Government’s motions, and where relevant, such facts — as they appear in the present state of the record — will be alluded to.

The Swine Flu Immunization Program was the rather hurried Congressional response to what it perceived as “a potential national emergency of severe proportions.” 2 During the Senate floor debates, Senator Javits, one of the Act’s cosponsors, explained the dilemma which confronted the legislators in dealing with the question of liability of program participants: 3

Unfortunately, the behavior of the insurance companies with respect to effectively preventing the vaccine to be made available to the American people has placed us in the tragic position of also having to create an alternative remedy for persons injured as a result of inoculation with the vaccine under the immunization program. 4

In short, since the insurance companies had refused liability coverage to the drug manufacturers involved in the program, and since time for exploring alternative *234 measures was severely limited, Congress chose the rather innovative approach of channeling all personal injury claims by the program “casualties” through the administrative process of the Federal Tort Claims Act. The pertinent portion of the Act outlining this scheme is as follows:

. all such claims will be asserted directly against the United States under section 1346(b) of title 28, United States Code, and chapter 171 of such title, (relating to tort claims procedure) except as otherwise specifically provided in this subsection.
(2) (A) The United States shall be liable with respect to claims submitted after September 30,1976 for personal injury or death arising out of the administration of swine flu vaccine under the swine flu program and based upon the act or omission of a program participant in the same manner and to the same extent as the United States would be liable in any other action brought against it under such section 1346(b) and chapter 171, except that—
(i) the liability of the United States arising out of the act or omission of a program participant may be based on any theory of liability that would govern an action against such program participant under the law of the place where the act or omission occurred, including negligence, strict liability in tort, and breach of warranty . . ” [42 U.S.C. § 247b(k)(l)(B) and (k)(2), (4)]

Congress was careful to make the foregoing remedy the exclusive one for personal injury or death resulting from inoculation under the program:

(3) The remedy against the United States prescribed by paragraph (2) of this subsection for personal injury or death arising out of the administration of the swine flu vaccine under the swine flu program shall be exclusive of any other civil action or proceeding for such personal injury or death against any employee of the Government (as defined in section 2671 of Title 28,) or program participant whose act or omission gave arise to the claim. [42 U.S.C. § 247b(k)(3)]

Upon the filing of the instant action against the defendant drug companies, the Government interceded, and, pursuant to 42 U.S.C. § 247b(k)(5)(A), the Attorney General (through his designate) certified that the suit arose out of an inoculation under the swine flu program. In accordance with that certification, the Government now seeks substitution and dismissal.

The plaintiffs objections to the Government’s motions will be addressed in the order in which they have been advanced.

Plaintiff asserts initially that the Act permits the maintenance of a suit for negligence directly against the drug manufacturers. In support of this assertion plaintiff cites the “Congressional findings” section of the Act, 42 U.S.C. § 247b(k) (1)(A), wherein is recited the necessity “to protect such . . . organizations against liability for other than their own negligence.” (emphasis supplied). From this phrase plaintiff concludes that Congress’ unmistakable intent was to permit common-law suits alleging negligent conduct on the part of drug manufacturers.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Flood v. Wyeth Laboratories, Inc.
183 Cal. App. 3d 1272 (California Court of Appeal, 1986)
Low v. United States
463 F. Supp. 948 (E.D. Virginia, 1978)
Heitz v. County of Sacramento
87 Cal. App. 3d 754 (California Court of Appeal, 1978)
Jones v. Wyeth Laboratories, Inc.
457 F. Supp. 35 (W.D. Arkansas, 1978)

Cite This Page — Counsel Stack

Bluebook (online)
433 F. Supp. 231, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wolfe-v-merrill-national-laboratories-inc-tnmd-1977.